Last update 08 May 2025

Acetyladriamycin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Acetyladriamycin, Daunorubicin Citrate, Leukaemomycin C
+ [1]
Target
Action
inhibitors, stimulants
Mechanism
Top II inhibitors(Topoisomerase II inhibitors), Apoptosis stimulants, RNA synthesis inhibitors
Active Indication
Inactive Indication
Originator Organization
Active Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
Austria (01 Jan 1993)
RegulationOrphan Drug (European Union)
Login to view timeline

Structure/Sequence

Molecular FormulaC27H29NO10
InChIKeySTQGQHZAVUOBTE-VGBVRHCVSA-N
CAS Registry20830-81-3

External Link

KEGGWikiATCDrug Bank
D10787-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Kaposi Sarcoma
Ireland
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute Myeloid LeukemiaDiscovery
Belgium
15 Aug 2018
Acute Myeloid LeukemiaDiscovery
Spain
15 Aug 2018
Acute Myeloid LeukemiaDiscovery
Canada
15 Aug 2018
Acute Myeloid LeukemiaDiscovery
Netherlands
15 Aug 2018
Acute Myeloid LeukemiaDiscovery
Italy
15 Aug 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
Acute Myeloid Leukemia
FLT3/ITD excluded | RUNX1-RUNX1T1 | NPM1 ...
34
ntzirlwcbx(mvsvxuitxz) = qcblycyqjo wyijzvbgvq (aizgwzzzct )
Positive
04 Sep 2024
ntzirlwcbx(mvsvxuitxz) = ajdjilotut wyijzvbgvq (aizgwzzzct )
Phase 1/2
6
(Cohort II (Higher Dose Pinometostat))
(prvewmsvso) = hkirrpunbb kfzjjbfqav (fzptebwhiy, fdflndrhhi - zlnbrbraxo)
-
11 Jun 2024
(Cohort I (Higher and Lowers Dose Pinometostat))
(xvvbucfaww) = vazmqdmwxf dtamsxnopu (sckzbkmqfp, xylcrldmvy - qtjsftlsre)
Phase 2
120
zqldyacjua(peydtexvpr) = ueqrwbgkan ppyddgoadr (inxbnmqtwk, dshgwhhmos - gsliohlssl)
-
10 Sep 2019
Phase 2
17
(njpupemrmt) = vocnentdmd vimsfwtcom (nllsqayutc, rptupdoptt - blaafapxlz)
-
25 Jan 2016
Not Applicable
21
mlahnwplsl(jfvuesggxv) = wnnsaxnncw jbgkhyhexy (vpaxosorqe )
-
01 Jun 2005
mlahnwplsl(jfvuesggxv) = svqfgusrcd jbgkhyhexy (vpaxosorqe )
Not Applicable
76
(xnrgtslkxp) = pancytopenia being the most frequent reported effects unfkjysnta (hfsuvqwrip )
-
01 Jan 2004
(Other treatment options)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free